Placebo-Controlled, Dose-Blinded, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Polyphenon E (EGCG) as Monotherapy for 14 Days in Antiretroviral Naïve and Experienced, HIV-1-Infected Subjects

Trial Profile

Placebo-Controlled, Dose-Blinded, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Polyphenon E (EGCG) as Monotherapy for 14 Days in Antiretroviral Naïve and Experienced, HIV-1-Infected Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Polyphenon E (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top